安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Capstan Therapeutics
Capstan Therapeutics Home; Company; Pipeline; Science Platform; News Publications; Company; Science Platform; Pipeline; Culture Careers
- P Hours after R N S N t e N 60 N t e N T o c t e A Novel Product . . .
Capstan’s proprietary lipid nanoparticle is a non-viral dose-tunable system designed for increased tolerability and biodegradability to allow for repeat in vivo dosing CPTX2309 IS MADE UP OF THREE COMPONENTS: 1 LNP DELIVERY VEHICLE 2 CD8 TARGETING BINDERS 3 ENHANCED ANTI-CD19 CAR mRNA
- Company - Capstan Therapeutics
We are a diverse team of experts integrating advancements in CAR-T therapy, mRNA, and LNPs, with rigorous focus to engineer transformative medicines
- Capstan Therapeutics to Present Preclinical Data on Lead In Vivo . . .
Capstan’s CellSeeker™ technology has the potential to generate transformative therapies with possible applications across a broad range of disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders
- Capstan Therapeutics Announces $175M Oversubscribed Series B Financing . . .
SAN DIEGO, March 20, 2024 – Capstan Therapeutics, Inc (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP), today announced the successful closing of a $175M oversubscribed Series B financing
- Capstan Therapeutics Presents Preclinical Data on Lead In Vivo CAR-T . . .
Capstan’s CellSeeker™ technology has the potential to generate transformative therapies with possible applications across a broad range of disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders
- 1500 Profound B Cell Depletion and Repopulation with Predominantly . . .
1Capstan Therapeutics, Inc ; San Diego, California, USA 2University of Pennsylvania, Philadelphia, Pennsylvania, USA Ex vivo chimeric antigen receptor (CAR) T cell therapies have revolutionized cancer treatment and have demonstrated significant clinical activity in various autoimmune disease indications Despite the success of
- Capstan Therapeutics Launches with $165 Million to Deliver on the . . .
Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need The core technology comprises targeted Lipid Nanoparticles (tLNPs) to enable engineering or ablation of pathogenic cells in the body
|
|
|